LENZ Therapeutics secured FDA approval for VIZZ, the first aceclidine-based eye drop for presbyopia, in mid-2025 and launched it commercially in the U.S. since August 2025. Despite this milestone, the company remains unprofitable with substantial operating losses and negative cash flow reflecting early commercialization investments. LENZ’s growth depends on market adoption of VIZZ within the large U.S. presbyopia population, scaling sales efforts, and protecting intellectual property amid competitive pressures. International licensing extends reach but increases reliance on partners. Monitoring sales traction, competitive landscape, and regulatory developments will be critical to assessing LENZ’s trajectory.